Topic: Ngs
Top 25 Biotech CEOs of 2020 - Soheil Shams
Since the advent of advanced genomics, and the subsequent rise of automation, the data generated in clinical testing and research sees a 100 fold increase each year making the storage, security and management of patient data quite a daunting task for companies to mine the data to find the factors that drive a patient’s disease. That’s where BioDiscovery comes in. Their flagship solution NxClinical, is a unique software tool for integrated analysis of copy number, sequence variants, and allelic changes obtained from multiple technologies. The solution combines NGS and Array data through advanced mining and filtering techniques which allows the data to be clear and digestible for clinicians.
BioDiscovery launches the NxClinical Center of Excellence initiative with Victorian Clinical Genetics Services as its first partner
BioDiscovery launches the NxClinical Center of Excellence initiative with Victorian Clinical Genetics Services as its first partner
BioDiscovery’s NxClinical software augments PerkinElmer Genomics newborn screening and genomic testing services in labs around the world
PerkinElmer Genomics has selected BioDiscovery's NxClinical software as its choice for genomic data analysis for its services.
BioDiscovery releases Nexus Copy Number 10.0, a single solution for copy number estimation from arrays, WES, WGS, shallow, and targeted sequencing
Nexus Copy Number 10.0 is a highly robust, intuitive, and multi-platform software for both copy number calling and downstream statistical analyses. A key feature of Nexus Copy Number is its ability to derive high quality copy number calls from many flavors of NGS (whole exome, whole genome, shallow, targeted panel, and normal depth of coverage sequencing).
BioDiscovery launches NxClinical 4.1, a comprehensive system allowing interpretation of variants of any size from SNVs to large CNVs
NxClinical 4.1 is a unique software solution for integration of copy number, sequence variants, and allelic changes obtained from microarray and NGS technologies. NxClinical 4.1 allows combined analysis and interpretation of all genomic variants on a single, platform agnostic system.
BioDiscovery Inc. Forms Partnership with Be Creative Lab (Beijing) Co. Ltd. For Distribution of NxClinical Software
BioDiscovery announced today an agreement with Be Creative Lab in Beijing, China to be the exclusive reseller and distributor of BioDiscovery products in China.
BioDiscovery launches NxClinical 4.0, a unique system allowing analysis and interpretation of CNV, SNV, and AOH from a single NGS assay
BioDiscovery launches NxClinical 4.0, a unique system allowing analysis and interpretation of CNV, SNV, and AOH from a single NGS assay.
BioDiscovery releases Nexus Copy Number 9.0 with improved copy number estimation from NGS, including targeted panels and shallow sequencing
The new features in Nexus Copy Number 9.0 really enhance the usability of WES, WGS, targeted panels and low-pass sequencing for copy number analysis.
GENALICE and BioDiscovery Partner to Empower Rapid NGS Data Interpretation
GENALICE and BioDiscovery announce a co-marketing partnership to offer their products together as a turn-key end-to-end solution for the use of next-generation sequencing (NGS) data to interpret genomes.
BioDiscovery to announce NxClinical 3.0, a new software to unite data from arrays and NGS, at ASHG 2016
NxClinical 3.0 will be launched during the ASHG 2016 Meeting, October 18-21 in Vancouver, BC, Canada
